Galectin Therapeutics Inc.
GALT
|
$3.4
0.0%
160K
|
Health Technology
(0.0% 1d) (58.9% 1m) (71.7% 1y) (0.0% 2d) (-13.0% 3d) (-19.0% 7d) (-54.59% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 210,472,485
http://www.galectintherapeutics.com
Sec Filling | Patents | 7 employees
(US) Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
skin cancer galectin-3
add to watch list Paper trade email alert is off
Press-releases
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Published: 2024-03-29 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
| Email alert
Add to watchlist
business update therapeutics financial results
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: -0.5%
H: 4.5%
C: -1.5%
therapeutics
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -7.14%
business update therapeutics financial results
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -7.14%
business update therapeutics financial results
Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.4 0.0% 160K
|
Health Technology
| Email alert
Add to watchlist
GLMD | $0.336 -5.17% -5.57% 46K
|
Health Technology
| Email alert
Add to watchlist
GNFT | $3.63 4.03% 3.4K
|
Health Technology
| Email alert
Add to watchlist
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
IVA | $3.22 -2.72% -2.8% 9.1K
|
Health Technology
| Email alert
Add to watchlist
MDGL M | $228.46 -1.94% -1.98% 250K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
| Email alert
Add to watchlist
IVEVF | $3.73 0% 1K
|
n/a
| Email alert
Add to watchlist
liver disease global nash market
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: 1.98%
H: 0.49%
C: -2.43%
liver therapeutics
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: -0.98%
H: 1.98%
C: -0.99%
conference therapeutics nash
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: 0.0%
H: 2.91%
C: -0.49%
therapeutics
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.4 0.0% 160K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Last 48 Hours Insiders Buying
IZEA | $2.5 -2.4% 8.6K
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 1.05% 1.4M
|
Finance
|
22:30
CTRN P 18090 | $22.46 -1.01% -1.02% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.795 2.38% 0.18% 35K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 3.1M
|
Health Technology
|
16:30
RMCF | $3.51 -3.7% -3.85% 3.8K
|
Consumer Non-Durables
|
20:10